Artemisinin remodeled breast cancer TME by increasing the numbers of tumorsuppressive CTLs and CD4+/IFN-γ+ Th1 cells, while concomitantly decreasing the numbers of tumorsupportive FOXP3+ Treg and T-bet+ MDSCs (73). Here, CD4 is linked to breast carcinoma.